Technology
Posters
Oral Presentation given to the American Association for Cancer Research (AACR) Annual Meeting 2024
Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients with Stage IV NSCLC
W. Theelen, M. Perol, K. Cuppens, I. Demedts, F. Borm, B. Biesma, E. Wauters, B. Colinet, E.-L. Buchmeier, F. Althoff, E. Pons-Tostivint, C. Van de Kerkhove, D. Moro-Sibilot, A. Sibille, S. Derijcke, M. Skrzypski, J. Plumas, B. De Vos, C. Debruyne, F. Cantero, S. Adriaenssens, F. Renard, J. Vansteenkiste;
Presented April 7, 2024
Poster presented to AACR Annual Meeting 2024
PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti-PD-1 treatment in patients with non-small cell lung cancer
J. Plumas, A. Sibille, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, W. Theelen, B. Biesma, F. Borm, E. Wauters, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, B. De Vos, B. Colinet, D. Moro-Sibilot, M. Perol, E. Buchmeier, M. Skrzypski, K. Cuppens, J. Vansteenkiste
Presented April 7, 2024
Oral Presentation given to the 49th annual meeting of the Korean Cancer Association & 9th international Cancer Conference
A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands tumor-specific CD8+ T cells of lung cancer patients
S-E. Kim, D. Hannani, E. Leplus, D. Laurin, B. Caulier, C. Aspord, N. Madelon, E. Bourova-Flin, C. Brambilla, E. Brambilla, A-C. Toffart, K. Laulagnier, L. Chaperot, J. Plumas
Presented June 15, 2023
Poster presented to 20th CIMT Annual Meeting
Induction of circulating antitumor specific CD8+ T cells in patients with non-small cell lung cancer treated with an allogeneic plasmacytoid dendritic-cell based cancer vaccine with or without anti- PD-1 treatment
S. Michel, I. Demedts, A. Sibille, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Perol, E.-L. Buchmeier, K. Cuppens, J. Vansteenkiste, J. Plumas
Presented May 5, 2023
Poster presented to ESMO Iummuno-Oncology Congress 2022
The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti- PD-1 treatment in patients with non-small cell lung cancer
A. Sibille, J. Plumas, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Pérol, E. Buchmeier, K. Cuppens, J. Vansteenkiste
Presented December 8, 2022
Check the document
Poster presented to ESMO 2022 Annual Meeting
Open-label, dose-escalation, phase I/II study to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with non-small-cell lung cancer (NSCLC).
J. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, K. Cuppens, S. Derijcke, L. Greillier, J. Jurgens, D. Moro-Sibilot, M. Pérol, M. Sebastian, M. Skrzypski, W. Theelen, C. Van De Kerkhove, M. Collodoro, J. Plumas, C. Debruyne, A. Sibille
Presented September 12, 2022
Check the document
eTalk given to the 18th CIMT Annual Meeting
Priming and expansion of functional antitumor T-cells in melanoma patients: results of phase I clinical trial with GeniusVac-Mel4, an innovative cancer vaccine based on a plasmacytoid dendritic cell line.
J. Charles, L. Chaperot, D. Hannani, J. Bruder Costa, I. Templier, S. Trabelsi, H. Gil, A. Moisan, V. Persoons, H. Hegelhofer, E. Schir, J.-L. Quesada, C. Mendoza, C. Aspord, O. Manches, P. Coulie, A. Khammari, B. Dreno, M.-T. Leccia, J. Plumas.
Presented: May 10-12, 2022
Check the document
eTalk given to the 18th CIMT Annual Meeting
The retroviral engineering of a human plasmacytoid dendritic cell-based vaccine allowed the priming and expansion of multispecific viral and tumor antigen-specific T-cells in multiple HLA contexts.
K. Lenogue, A. Walencik, K. Laulagnier, J.-P. Molens, H. Benlalam, B. Dreno, P. Coulie, M. Pule, L. Chaperot, J. Plumas
Presented: May 10-12, 2022
Check the document
Poster presented to ESMO Iummuno-Oncology Congress 2022
The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti- PD-1 treatment in patients with non-small cell lung cancer
A. Sibille, J. Plumas, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Pérol, E. Buchmeier, K. Cuppens, J. Vansteenkiste
Presented December 8, 2022
Check the document
Poster presented to ESMO 2022 Annual Meeting
Open-label, dose-escalation, phase I/II study to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with non-small-cell lung cancer (NSCLC).
J. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, K. Cuppens, S. Derijcke, L. Greillier, J. Jurgens, D. Moro-Sibilot, M. Pérol, M. Sebastian, M. Skrzypski, W. Theelen, C. Van De Kerkhove, M. Collodoro, J. Plumas, C. Debruyne, A. Sibille
Presented September 12, 2022
Check the document
eTalk given to the 18th CIMT Annual Meeting
Priming and expansion of functional antitumor T-cells in melanoma patients: results of phase I clinical trial with GeniusVac-Mel4, an innovative cancer vaccine based on a plasmacytoid dendritic cell line.
J. Charles, L. Chaperot, D. Hannani, J. Bruder Costa, I. Templier, S. Trabelsi, H. Gil, A. Moisan, V. Persoons, H. Hegelhofer, E. Schir, J.-L. Quesada, C. Mendoza, C. Aspord, O. Manches, P. Coulie, A. Khammari, B. Dreno, M.-T. Leccia, J. Plumas.
Presented: May 10-12, 2022
Check the document
eTalk given to the 18th CIMT Annual Meeting
The retroviral engineering of a human plasmacytoid dendritic cell-based vaccine allowed the priming and expansion of multispecific viral and tumor antigen-specific T-cells in multiple HLA contexts.
K. Lenogue, A. Walencik, K. Laulagnier, J.-P. Molens, H. Benlalam, B. Dreno, P. Coulie, M. Pule, L. Chaperot, J. Plumas
Presented: May 10-12, 2022
Check the document
Poster presented to European Lung Cancer Virtual Congress (ELCC 2021 Virtual)
An open-label, dose escalation, Phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with Non-small cell lung cancer (NSCLC).
J. Bennouna, A. Sibille, C. Debruyne, B. Colinet, I. Demedts, S. Derijcke, L. Greillier, J. Jurgens, H. Lena, D. Moro-Sibilot, M. Pérol, X. Quantin, N. Reinmuth, M. Sebastian, M. Genin, J. Plumas, J. Vansteenkiste
Presented: March 25 – 27, 2021
Check the document
Poster presented to ESMO Immuno-Oncology Congress 2017
Priming and expansion of neo-antigen specific-T cells thanks to an off-the-self cell-based drug product.
Plumas J, De Sousa Alves PM, Leplus E, Chaperot L, Hannani D
December 7-10, 2017
Check the document
